Mutations in the genes encoding the transcription factors hepatocyte nuclear factor 1 alpha (HNF1A) and 4 alpha (HNF4A) in maturity-onset diabetes of the young

被引:149
作者
Ellard, Sian
Colclough, Kevin
机构
[1] Royal Devon & Exeter NHS Trust, Dept Mol Genet, Exeter EX2 5DW, Devon, England
[2] Peninsula Med Sch, Inst Biomed & Clin Sci, Exeter, Devon, England
关键词
diabetes; MODY; MODY1; MODY3; HNF1A; TCF1; HNF4A; clinical management;
D O I
10.1002/humu.20357
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Maturity-onset diabetes of the young (MODY) is a monogenic form of diabetes mellitus characterized by autosomal dominant inheritance, early age of onset (often < 25 years of age), and pancreatic beta-cell dysfunction. MODY is both clinically and genetically heterogeneous, with six different genes identified to date; glucokinase (GCK), hepatocyte nuclear factor-1 alpha (HNFIA, or TCF1), hepatocyte nuclear factor-4 alpha (HNF4A), insulin promoter factor-1 (IPF1 or PDX1), hepatocyte nuclear factor-1 beta (HNF1B or TCF2), and neurogenic differentiation 1 (NEUROD1). Mutations in the HNFIA gene are a common cause of MODY in the majority of populations studied. A total of 193 different mutations have been described in 373 families. The most common mutation is Pro291fs (P291fsinsC) in the polycytosine (poly C) tract of exon 4, which has been reported in 65 families. HNF4A mutations are rarer; 31 mutations reported in 40 families. Sensitivity to treatment with sulfonylurea tablets is a feature of both HNFIA and HNF4A mutations. The identification of an HNF1A or 4A gene mutation confirms a diagnosis of MODY and has important implications for clinical management.
引用
收藏
页码:854 / 869
页数:16
相关论文
共 148 条
  • [1] Early-onset type 2 diabetes:: Metabolic and genetic characterization in the Mexican population
    Aguilar-Salinas, CA
    Reyes-Rodríguez, E
    Ordóñez-Sánchez, ML
    Torres, MA
    Ramírez-Jiménez, S
    Domínguez-López, A
    Martínez-Francois, JR
    Velasco-Pérez, ML
    Alpizar, M
    García-García, E
    Gómez-Pérez, F
    Rull, J
    Tusié-Luna, MT
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (01) : 220 - 226
  • [2] Adult-onset atypical (type 1) diabetes - Additional insights and differences with type 1A diabetes in a European Mediterranean population
    Aguilera, E
    Casamitjana, R
    Ercilla, G
    Oriola, J
    Gomis, R
    Conget, I
    [J]. DIABETES CARE, 2004, 27 (05) : 1108 - 1114
  • [3] A prevalent amino acid polymorphism at codon 98 (Ala98Val) of the hepatocyte nuclear factor-1α is associated with maturity-onset diabetes of the young and younger age at onset of type 2 diabetes in Asian Indians
    Anuradha, S
    Radha, V
    Deepa, R
    Hansen, T
    Carstensen, B
    Pedersen, O
    Mohan, V
    [J]. DIABETES CARE, 2005, 28 (10) : 2430 - 2435
  • [4] A novel missense mutation in the homeodomain of the hepatocyte nuclear factor-1α/maturity-onset diabetes of the young 3 in a Japanese early-onset type 2 diabetic patient and time-course of glucose-stimulated insulin secretion
    Awata, T
    Kurihara, S
    Inoue, K
    Inoue, I
    Takei, S
    Ishii, C
    Negishi, K
    Namai, K
    Kanazawa, Y
    Kuzuya, T
    Katayama, S
    [J]. DIABETES CARE, 1998, 21 (09) : 1569 - 1571
  • [5] STRUCTURE OF THE GENE ENCODING HEPATOCYTE NUCLEAR FACTOR 1 (HNF1)
    BACH, I
    PONTOGLIO, M
    YANIV, M
    [J]. NUCLEIC ACIDS RESEARCH, 1992, 20 (16) : 4199 - 4204
  • [6] MORE POTENT TRANSCRIPTIONAL ACTIVATORS OR A TRANSDOMINANT INHIBITOR OF THE HNF1 HOMEOPROTEIN FAMILY ARE GENERATED BY ALTERNATIVE RNA PROCESSING
    BACH, I
    YANIV, M
    [J]. EMBO JOURNAL, 1993, 12 (11) : 4229 - 4242
  • [7] Familial liver adenomatosis associated with hepatocyte nuclear factor 1α inactivation
    Bacq, Y
    Jacquemin, E
    Balabaud, C
    Jeannot, E
    Scotto, B
    Branchereau, S
    Laurent, C
    Bourlier, P
    Pariente, D
    De Muret, A
    Fabre, M
    Bioulac-Sage, P
    Zucman-Rossi, J
    [J]. GASTROENTEROLOGY, 2003, 125 (05) : 1470 - 1475
  • [8] Barbetti F, 1998, DIABETES, V47, pA399
  • [9] Retrospective study of outcomes in Hyalgan®-treated patients with osteoarthritis of the knee
    Barrett, JP
    Siviero, P
    [J]. CLINICAL DRUG INVESTIGATION, 2002, 22 (02) : 87 - 97
  • [10] Bartolotta E, 1999, DIABETOLOGIA, V42, pA114